Evidence map›Paper›PMID 32615951›Full record

ArticleBMC public health2020

Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.

William C W Wong, Nancy S Yang, Jingjing Li, Hang Li, Eric Y F Wan, Thomas Fitzpatrick, Yuan Xiong, Wai-Kay Seto, Polin Chan, Ruihong Liu and 2 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Hepatitis C virus micro-elimination: Where do we stand?World journal of gastroenterology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

William C W WongDepartment of General Practice, HKU-Shenzhen Hospital, Shenzhen, China.
Nancy S YangUniversity of Minnesota Medical School, Minneapolis, MN, USA.
Jingjing LiUniversity of North Carolina Project-China, 1 Global Health Center Office, 2nd Floor of Lao Gan Building, No. 7 Lujing Road, Yuexiu District, Guangzhou City, Guangdong Province, Guangzhou, China. jingjingli@seshglobal.org.ORCID http://orcid.org/0000-0002-9677-0215
Hang LiDepartment of General Practice, HKU-Shenzhen Hospital, Shenzhen, China.
Eric Y F WanDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, China.
Thomas FitzpatrickUniversity of Washington, Seattle, WA, USA.
Yuan XiongUniversity of North Carolina Project-China, 1 Global Health Center Office, 2nd Floor of Lao Gan Building, No. 7 Lujing Road, Yuexiu District, Guangzhou City, Guangdong Province, Guangzhou, China.
Wai-Kay SetoDepartment of Medicine, The University of Hong Kong, Hong Kong, China.
Polin ChanWorld Health Organization Western Pacific Regional Office, Manila, Philippines.
Ruihong LiuDepartment of General Practice, HKU-Shenzhen Hospital, Shenzhen, China.
Weiming TangUniversity of North Carolina Project-China, 1 Global Health Center Office, 2nd Floor of Lao Gan Building, No. 7 Lujing Road, Yuexiu District, Guangzhou City, Guangdong Province, Guangzhou, China.
Joseph D TuckerUniversity of North Carolina Project-China, 1 Global Health Center Office, 2nd Floor of Lao Gan Building, No. 7 Lujing Road, Yuexiu District, Guangzhou City, Guangdong Province, Guangzhou, China.
University of Hong Kong - Shenzhen Hospital · CNGuangzhou University · CNUniversity of Hong Kong · HKUniversity of Minnesota Medical Center · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · USWorld Health Organization Regional Office for the Western Pacific · PH

Funding

Gilead Sciences IN-CN-987-5376World Health Organization 001
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is a growing public health problem with a large disease burden worldwide. In China many people living with HCV are unaware of their hepatitis status and not connected to care and treatment. Crowdsourcing is a technique that invites the public to create health promotion materials and has been found to increase HIV testing uptake, including in China. This trial aims to evaluate crowdsourcing as a strategy to improve HCV awareness, testing and linkage-to-care in China.

methodsA randomized controlled, two-armed trial (RCT) is being conducted in Shenzhen with 1006 participants recruited from primary care sectors of The University of Hong Kong-Shenzhen Hospital. Eligible participants are ≥30 years old; a resident in Shenzhen for at least one month after recruitment; no screening for HCV within the past 12 months and not known to have chronic HCV; and, having a WeChat social media account. Allocation is 1:1. Both groups will be administered a baseline and a follow-up survey (4-week post-enrollment). The intervention group will receive crowdsourcing materials to promote HCV testing once a week for two weeks and feedback will be collected thereafter, while the control group will receive no promotional materials. Feedback collected will be judged by a panel and selected to be implemented to improve the intervention continuously. Those identified positive for HCV antibodies will be referred to gastroenterologists for confirmation and treatment. The primary outcome will be confirmed HCV testing uptake, and secondary outcomes include HCV confirmatory testing and initiation of HCV treatment with follow-ups with specialist providers. Data will be collected on Survey Star DISCUSSION: This will be the first study to evaluate the impact of crowdsourcing to improve viral hepatitis testing and linkage-to-care in the health facilities. This RCT will contribute to the existing literature on interventions to improve viral hepatitis testing in primary care setting, and inform future strategies to improve HCV care training for primary care providers in China.

trial registrationChinese Clinical Trial Registry. ChiCTR1900025771. Registered September 7th, 2019, http://www.chictr.org.cn/showprojen.aspx?proj=42788.

Indexed as

AdultChinaCrowdsourcingFemaleHealth PromotionHepacivirusHepatitis CHepatitis C AntibodiesHepatitis C, ChronicHumansMass ScreeningPrimary Health CareRandomized Controlled Trials as TopicSocial MediaHepatitis C AntibodiesChinaCrowdsourcingHepatitis C virus (HCV)Linkage-to-carePrimary careTesting

Identifiers

PMID32615951
PMCPMC7330974
OpenAlexW3040609414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.